Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer

2012 ◽  
Vol 22 (6) ◽  
pp. 1328-1335 ◽  
Author(s):  
Andrea M. Tavlarides ◽  
Steven C. Ames ◽  
Nancy N. Diehl ◽  
Richard W. Joseph ◽  
Erik P. Castle ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Surgical Treatment ◽  
Sexual Function ◽  
Localized Prostate Cancer ◽  
Men 1 ◽  
Cancer Aggressiveness

scholarly journals Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation

2020 ◽  
Author(s):  
Heikki Seikkula ◽  
Peter J. Boström ◽  
Karri Seppä ◽  
Janne Pitkäniemi ◽  
Nea Malila ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Localized Prostate Cancer ◽  
Curative Treatment ◽  
Entire Study ◽  
Treatment Groups ◽  
Age Cohorts ◽  
Cancer Aggressiveness

Abstract Background: Androgen deprivation therapy (ADT) remains a primary treatment for localized prostate cancer (PCa) even though there is no evidence that its use is beneficial in the absence of curative treatment.Methods: Men aged ≥70 years (n = 16534) diagnosed with localized PCa from 1985 to 2014 and managed either with primary observation or ADT in the absence of curative treatment were included. The cases were identified from the population-based Finnish Cancer Registry. We estimated the standardized mortality ratios (SMR) for overall mortality by treatment group. We determined the relative risk (RR) of PCa-specific mortality (PCSM) and other-cause mortality between the two treatment groups. Survival was determined using the life table method. Two age groups (70–79 years and ≥80 years) and three calendar time cohorts (1985–1994, 1995–2004, and 2005–2014) were compared following adjustment of propensity score matching between the treatment groups with four covariates (age, year of diagnosis, educational level, and hospital district). Follow-up continued until death or until December 31, 2015. Results: Patients in the observation group had lower overall SMRs than those in the ADT group in both age cohorts over the entire study period. PCSM was higher in men aged 70–79 years undergoing primary ADT compared to those managed by observation only (RR: 1.70, 95% confidence interval [CI]: 1.29–2.23 [1985–1994]; RR 1.55, 95% CI: 1.35–1.84 [1995–2004]; and RR 2.71, 95% CI: 2.08–3.53 [2005–2014]); p = 0.005 for periodic trend. A similar trend over time was also observed in men aged >80 years; (p for age–period interaction = 0.237). Overall survival was also higher among men in their 70’s managed by observation compared to those undergoing ADT.Conclusions: Primary ADT within four months period from diagnosis is not associated with improved long-term overall survival or decreased PCSM compared to primary conservative management for men with localized PCa. However, this observational study’s conclusions should be weighted with confounding factors related to cancer aggressiveness and comorbidities.

scholarly journals Relationship between sexual function and prostate-specific antigen bounce after iodine-125 permanent implant brachytherapy for localized prostate cancer

2014 ◽  
Vol 21 (7) ◽  
pp. 658-663 ◽  
Author(s):  
Kiyoaki Nishihara ◽  
Makoto Nakiri ◽  
Katsuaki Chikui ◽  
Shigetaka Suekane ◽  
Kei Matsuoka ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Sexual Function ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Localized Prostate Cancer ◽  
Iodine 125 ◽  
Permanent Implant

scholarly journals Functional Imaging of Localized Prostate Cancer Aggressiveness Using 11C-Acetate PET/CT and 1H-MR Spectroscopy

2010 ◽  
Vol 51 (11) ◽  
pp. 1676-1683 ◽  
Author(s):  
I. Jambor ◽  
R. Borra ◽  
J. Kemppainen ◽  
V. Lepomaki ◽  
R. Parkkola ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Functional Imaging ◽  
Mr Spectroscopy ◽  
Localized Prostate Cancer ◽  
1H Mr Spectroscopy ◽  
Cancer Aggressiveness ◽  
Pet Ct

Pre-treatment nomogram to predict potency after treatment for localized prostate cancer.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 32-32 ◽  
Author(s):  
Joseph Zabell ◽  
Martin G. Sanda ◽  
Mark S. Litwin ◽  
Jose Francisco Suarez ◽  
Meredith M. Regan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Sexual Function ◽  
External Beam Radiotherapy ◽  
Multivariable Analysis ◽  
The United States ◽  
Post Treatment ◽  
Localized Prostate Cancer ◽  
Patient Reported ◽  
Reported Data ◽  
Prospective Longitudinal

32 Background: Radical prostatectomy (RP), external beam radiotherapy (EBRT), and brachytherapy are commonly utilized treatments for localized prostate cancer and may negatively impact sexual function to varying degrees. Patient-, disease-, and treatment-specific factors may all impact post-treatment sexual function. We aimed to evaluate predictors of post-treatment impotency, and develop a prognostic nomogram using prospective, patient-reported data from multiple validated health-related quality-of-life (HRQOL) instruments. Methods: Between 1999 and 2011, patient-reported data regarding treatment-related effects on erectile function were obtained from 2668 patients enrolled in one of four prospective longitudinal HRQOL protocols from the United States and Spain. Patients were treated with RP (n=1,294), EBRT (n=630), or brachytherapy (n=744). Although different HRQOL instruments were used in each protocol, questions pertaining to quality and frequency of erections were identical across the different instruments. Patient responses were obtained at baseline and 2 years after treatment. The endpoint of the model was impotency at 2 years post-treatment. Logistic regression analysis was used to model clinical information and outcome data. Internal validation was performed using bootstrapping. Results: 1,306 patients were potent at baseline and had 24-month follow-up. Differences in baseline patient characteristics such as patient age, ethnicity, and disease severity existed between the treatment groups. The impotency rate at 2 years was 62%, 53%, and 41% for patients treated by RP, EBRT, and brachytherapy, respectively. In multivariable analysis, age, PSA, modality of treatment, frequency of preoperative erections, diabetes, and hypertension were associated with post-treatment impotency (all p<0.05). A nomogram based on the predictive parameters had a concordance index of 0.726 and predictions were well-calibrated with observed outcome. Conclusions: A validated nomogram that predicts 2-year risk of impotency after treatment of localized prostate cancer has been developed and is anticipated to be useful for patient counseling regarding treatment options.

Urodynamics study in patients with urinary incontinence, after surgical treatment of localized prostate cancer

Urologiia ◽  
2018 ◽  
Vol 6_2018 ◽  
pp. 14-18
Author(s):  
I.A. Aboyan Aboyan ◽  
V.E. Aboyan Aboyan ◽  
Yu.N. Orlov Orlov ◽  
S.M. Pakus Pakus ◽  
D.I. Pakus Pakus ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Urinary Incontinence ◽  
Surgical Treatment ◽  
Localized Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document